Adrian E. Fehn

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.

Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.

Journal: Blood advances

Published: July 29, 2025

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Journal: Blood advances

Published: July 29, 2025

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Journal: Blood advances

Published: July 29, 2025

Extensive non-clonal CAR T-cell expansion causing fatal hyperinflammatory syndrome with immune effector cell-associated hemophagocytic lymphohistiocytosis, cytokine release syndrome, and neurotoxicity syndrome.

Extensive non-clonal CAR T-cell expansion causing fatal hyperinflammatory syndrome with immune effector cell-associated hemophagocytic lymphohistiocytosis, cytokine release syndrome, and neurotoxicity syndrome.

Journal: Haematologica

Published: May 17, 2025

5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells.

5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells.

Journal: Neoplasia (New York, N.Y.)

Published: July 15, 2024

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome.

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome.

Journal: Bone marrow transplantation

Published: December 21, 2023

Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).

Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).

Journal: International journal of cancer

Published: July 18, 2020

Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.

Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.

Journal: Carcinogenesis

Published: May 13, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026